Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations
Academic Article
Publication Date:
2022
Short description:
Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations / Tausch, E., Ljungström, V., Agathangelidis, A., Zapatka, M., Scarfò, L., Jebaraj, B.M.C., Yosifov, D.Y., Müller, A., Munugalavadla, V., Degenhardt, J.D., Ghia, P., Rosenquist, R., Stilgenbauer, S.. - In: BLOOD. - ISSN 1528-0020. - 139:22(2022), pp. 3340-3344. [10.1182/blood.2021014550]
Iris type:
1.1 Articolo in rivista
Keywords:
Cell Line, Tumor; Drug Resistance, Neoplasm; Mutation; Purines; Up-Regulation; MAP Kinase Signaling System; Quinazolinones
List of contributors:
Tausch, Eugen; Ljungström, Viktor; Agathangelidis, Andreas; Zapatka, Marc; Scarfò, Lydia; Jebaraj, Billy Michael Chelliah; Yosifov, Deyan Y; Müller, Annika; Munugalavadla, Veerendra; Degenhardt, Jeremiah D; Ghia, Paolo; Rosenquist, Richard; Stilgenbauer, Stephan
Published in: